The American Journal of Medicine
Volume 123, Issue 5 , Pages 446-453 , May 2010

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?

Parts of these data were presented in poster format at the Heart Rhythm Society Annual Meeting, May 13-16, 2009.

  • Peter J. Zimetbaum, MD

      Affiliations

    • Harvard Medical School, Boston, Mass
    • Corresponding Author InformationRequests for reprints should be addressed to Peter J. Zimetbaum, MD, Director, Clinical Cardiology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215
    • ,
  • Amit Thosani, MD

      Affiliations

    • Harvard Medical School, Boston, Mass
    • ,
  • Hsing-Ting Yu, MPH

      Affiliations

    • Cerner LifeSciences, Beverly Hills, Calif
    • ,
  • Yan Xiong, MS

      Affiliations

    • Cerner LifeSciences, Beverly Hills, Calif
    • ,
  • Jay Lin, PhD

      Affiliations

    • sanofi-aventis, Bridgewater, NJ
    • ,
  • Prajesh Kothawala, MD, MPH

      Affiliations

    • Cerner LifeSciences, Beverly Hills, Calif
    • ,
  • Matthew Emons, MD, MBA

      Affiliations

    • Cerner LifeSciences, Beverly Hills, Calif

References 

  1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375
  2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–952
  3. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229–234
  4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988
  5. Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348–356
  6. Biblo LA, Yuan Z, Quan KJ, et al. Risk of stroke in patients with atrial flutter. Am J Cardiol. 2001;87:346–349A349
  7. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003;22:118–123
  8. Lip GY. Does atrial fibrillation confer a hypercoagulable state?. Lancet. 1995;346:1313–1314
  9. Chung NA, Belgore F, Li-Saw-Hee FL, et al. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?. Stroke. 2002;33:2187–2191
  10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (Analysis of pooled data from five randomized controlled trials). Arch Intern Med. 1994;154:1449–1457
  11. Connolly SJ. ATHENA: The effect of dronedarone on cardiovascular outcomes and stroke in patients with atrial fibrillation. Program and abstracts from the European Society of Cardiology Congress 2008. Germany: Munich; 2008;Clinical trials update 3
  12. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–1840
  13. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833
  14. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690–1696
  15. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–e354
  16. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501
  17. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):546S–592S
  18. van Walraven C, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003;163:936–943
  19. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870
  20. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99:295–304
  21. Lewis WR, Fonarow GC, LaBresh KA, et al. Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation. Am J Cardiol. 2009;103:227–231
  22. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004;164:55–60
  23. Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018–3026
  24. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40:235–240
  25. Waldo AL, Becker RC, Tapson VF, Colgan KJ. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46:1729–1736
  26. Meiltz A, Zimmermann M, Urban P, Bloch A. Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace. 2008;10:674–680
  27. Goldman HH, Frank RG, Burnam MA, et al. Behavioral health insurance parity for federal employees. N Engl J Med. 2006;354:1378–1386
  28. Chernew M, Gibson TB, Yu-Isenberg K, et al. Effects of increased patient cost sharing on socioeconomic disparities in health care. J Gen Intern Med. 2008;23:1131–1136
  29. Mark TL, Axelsen KJ, Mucha L, Sadkova Y. Racial differences in switching, augmentation, and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients. Am J Manag Care. 2007;13(Suppl 3):S72–S79
  30. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075–1079discussion 1081-1090
  31. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689–2696
  32. DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:650–656
  33. Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100:599–607
  34. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol. 2007;50:2156–2161
  35. Crystal E, Connolly SJ. Role of oral anticoagulation in management of atrial fibrillation. Heart. 2004;90:813–817

 Funding: Financial support for the preparation of this manuscript was provided by sanofi-aventis US, Inc. This funding was used for provision of editorial support by Elizabeth Harvey, PhD and Andrew Fitton, PhD of UBC Scientific Solutions.

 Conflict of Interest: Dr. Peter Zimetbaum is a research consultant to sanofi-aventis. Dr. Jay Lin is an employee of sanofi-aventis. Hsing-Ting Yu and Matthew Emons are employees of Cerner LifeSciences, which provided consulting services to sanofi-aventis. Yan Xiong and Prajesh Kothawala were employed by Cerner LifeSciences at the time the research was conducted.

 Authorship: All authors had access to the study data, and participated in analysis or interpretation of the data (or both), and preparation of the manuscript.

PII: S0002-9343(09)01114-0

doi: 10.1016/j.amjmed.2009.11.015

The American Journal of Medicine
Volume 123, Issue 5 , Pages 446-453 , May 2010

Article Tools

* Image Usage & Resolution